Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Helena Leonie Hanae Loer"'
1
Akademický článek
A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions
Autor: Christina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer, Matthias Schwab, Thorsten Lehr
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 7, Pp 1144-1159 (2024)
Abstract Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, da
Externí odkaz: https://doaj.org/article/1be7c6a61b9549f492988303267df6f2
Zobrazit plný text záznamu
2
Akademický článek
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions
Autor: Helena Leonie Hanae Loer, Christina Kovar, Simeon Rüdesheim, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer, Matthias Schwab, Thorsten Lehr
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 926-940 (2024)
Abstract The first‐generation tyrosine kinase inhibitor imatinib has revolutionized the development of targeted cancer therapy and remains among the frontline treatments, for example, against chronic myeloid leukemia. As a substrate of cytochrome P
Externí odkaz: https://doaj.org/article/a46afdd0540e4e8eb56c221dcc371740
Zobrazit plný text záznamu
3
Akademický článek
Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
Autor: Denise Feick, Simeon Rüdesheim, Fatima Zahra Marok, Dominik Selzer, Helena Leonie Hanae Loer, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1143-1156 (2023)
Abstract The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug–drug interaction (DDI) studies. However, as quinidine is also a subst
Externí odkaz: https://doaj.org/article/503a323dba2b45ac83fda9c9d5d71582
Zobrazit plný text záznamu
4
Akademický článek
Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
Autor: Helena Leonie Hanae Loer, Denise Feick, Simeon Rüdesheim, Dominik Selzer, Matthias Schwab, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Thorsten Lehr
Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 5, Pp 724-738 (2023)
Abstract The immunosuppressant and narrow therapeutic index drug tacrolimus is metabolized mainly via cytochrome P450 (CYP) 3A4 and CYP3A5. For its pharmacokinetics (PK), high inter‐ and intra‐individual variability can be observed. Underlying ca
Externí odkaz: https://doaj.org/article/8f442549019b44338f8e3c2b8a8de9ff
Zobrazit plný text záznamu
5
Akademický článek
Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
Autor: Helena Leonie Hanae Loer, Denise Türk, José David Gómez-Mantilla, Dominik Selzer, Thorsten Lehr
Publikováno v: Pharmaceutics, Vol 14, Iss 5, p 915 (2022)
The antiplatelet agent clopidogrel is listed by the FDA as a strong clinical index inhibitor of cytochrome P450 (CYP) 2C8 and weak clinical inhibitor of CYP2B6. Moreover, clopidogrel is a substrate of—among others—CYP2C19 and CYP3A4. This work pr
Externí odkaz: https://doaj.org/article/1d81298bd9614cba9f1a4ac9ab5723d7
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje